RE: ADS Split17 Dec 2025 15:29
Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.
Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25.
Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth.
Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales.
Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test.
Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease.
Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27.
Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position.
1000 × $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books.
You see where its going? Have some faith.
And perhaps more research than whining on a forum